All News
Trends and Innovations from Barcelona (6.20.2025)
Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.
Read Article
Pregnancy in SLE: Risks Extend Beyond Clinical Concerns
While clinical comorbidities such as lupus nephritis, hypertension, and thrombocytopenia have traditionally dominated risk assessments, new findings presented at EULAR 2025 spotlight the critical—and often underrecognized—role of social determinants of health (SDOH) in shaping maternal outcomes.
Read Article
Striking a ‘nerve’ in RA: understanding neuromodulation
Over the last 50 years, discoveries of connections between inflammation and the nervous system have been better understood.
Read Article
Rheumatoid arthritis incidence has risen to 17.9 million people globally -13.2% increase from 1990-2021. Fewer people are dying from RA, but disability-adjusted life Yrs have doubled. high sociodemographic index bore the heaviest burden. Smoking control policies is forecasted to https://t.co/YmWcinVdmE
Dr. John Cush RheumNow ( View Tweet)
#EULAR2025 TriNetX database study indicated that fibromyalgia patients who used glucagon-like peptide-1 (GLP-1) receptor agonist drugs were less likely to use opioids and to report pain, fatigue, and malaise compared with propensity-matched non-users https://t.co/ftm93VwW65 https://t.co/2wloutoX8a
Dr. John Cush RheumNow ( View Tweet)
Predictors and Outcomes in Systemic Sclerosis
The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will https://t.co/C4Pro6b0Jw
Dr. John Cush RheumNow ( View Tweet)
Expanding the IL-17 Therapeutic Landscape
IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. https://t.co/Q7Thp1HJAL
Dr. John Cush RheumNow ( View Tweet)
Putting IL17i into ‘focus’ for SpA-associated uveitis
The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than https://t.co/AUEct0FxmU
Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis: Hit hard and Early
Two studies found no significant benefit of early biologics over standard methotrexate treatment, but they did not focus on poor prognosis cases. The SPEED trial, funded by the NIHR, aimed to compare disease activity in 192 PsA patients https://t.co/pS9DdOOVCV
Dr. John Cush RheumNow ( View Tweet)
The Value of Kidney Biopsy in Autoimmune Diseases
Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/CA6Ak2scKb https://t.co/EK5wdpbzrl
Dr. John Cush RheumNow ( View Tweet)
EULAR Daily Recap: Day 3
Catch up on the biggest breakthroughs, standout sessions, and expert insights from day three of EULAR 2025. Listen to panelists break down the key highlights and what they mean for the future of rheumatology. Panelists: Drs. Yuz Yusof, Aurelie Najm, https://t.co/jmXUDV8odR
Dr. John Cush RheumNow ( View Tweet)
ALTO: Long-term Outcomes of APIPPRA
Dr. Mrinalini Dey interviews Professor Andrew Cope about abstract OP0004, on the long term outcome of APIPPRA patients - the ALTO study, at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/9wVZSXbi6r https://t.co/fm77qDoTwm
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – Day 4 Report
Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. https://t.co/ZJ1pHQJTbK
Dr. John Cush RheumNow ( View Tweet)
Toward Long-Term Prevention of Rheumatoid Arthritis: Are We Closer?
As earlier diagnosis and treatment of rheumatoid arthritis (RA) have resulted in greatly improved clinical outcomes, the focus of current research has now shifted to preventing the development of RA altogether. https://t.co/HGbXVLVuSC
Dr. John Cush RheumNow ( View Tweet)
Difficult to Treat Axial Spondyloarthritis
Drs. Antoni Chan and Martina Magrey discuss abstract POS0117 presented at the 2025 EULAR meeting in Barcelona.
https://t.co/isv05fzV1d https://t.co/Ji24s9qSZF
Links:
Dr. John Cush RheumNow ( View Tweet)
Lessons on Uveitis and AxSpA
Dr. Adela Castro reporting from the 2025 EULAR meeting in Barcelona
https://t.co/G0lDGDhpTh https://t.co/UWBSgTLyQm
Dr. John Cush RheumNow ( View Tweet)
DMARD Combinations in RA Treatment
Dr. Jiha Lee discusses abstract OP0195 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/lrZRDvWD0z https://t.co/PS4k2bCqet
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib's Place in the PsA Treatment Algorithm?
Dr. Eric Ruderman offers his perspective on where deucravacitinib will fit in the treatment algorithm and trials presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/6Ozrvr5IMt https://t.co/w7FJs4wir9
Dr. John Cush RheumNow ( View Tweet)
JAK Safety Update
Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/F8WzGohCj8 https://t.co/FguBLrmPzZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia
The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence (AI) and digital health technologies. Traditionally, treatment has centered around https://t.co/5CCpZqkm7K
Dr. John Cush RheumNow ( View Tweet)
